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At 16.5 kD, survivin is the smallest member of 
the inhibitor of apoptosis protein (IAP) family. 
Survivin contains a single BIR domain and a 
C-terminal α-helical coiled coil, but no RING 
fi   nger or other identifi   able domain typically 
found in IAPs (1). Currently, there are three 
lines of experimental evidence that support 
a role for survivin in suppression of apoptosis 
(2). First, overexpression of survivin has been 
shown to antagonize cell death initiated via the 
extrinsic or intrinsic apoptotic pathway. Sec-
ond, transgenic expression of survivin under 
the keratin 14 (K14) promoter inhibited apop-
tosis in vivo (3). Conversely, liver cells that 
were isolated from survivin heterozygous mice 
exhibited an increase in apoptosis upon treatment 
with a lower concentration of Fas ligand (4). 
Third, molecular antagonists of survivin, includ-
ing antisense, ribozymes, siRNA, and dominant-
negative mutants, resulted in caspase-dependent 
cell death and enhancement of apoptotic stimuli 
and anticancer activities in vivo (2). Although 
the role of survivin in conferring resistance to 
apoptosis is well established, the context in which 
it does so and the mechanisms by which it ac-
complishes this remains debatable. It is likely 
that survivin mediates its antiapoptotic eff  ect 
through association with other pro- or antiapop-
totic molecules (5–8).
Contrary to its role in apoptosis inhibition, 
survivin’s role in mitosis is unequivocal. Sur-
vivin inactivation has been shown to cause defects 
in chromosome alignment, spindle assembly 
checkpoint, and cytokinesis, with eventual cell 
death via mitotic catastrophe (9–12). In Cae-
norhabditis elegans, embryos and oocytes lacking 
the survivin homologue Bir-1 displayed chro-
mosomal and spindle defects (13). In addition, 
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homozygous survivin gene deletion in mice resulted in em-
bryonic lethality at embryonic day (E) 4.5, with cells exhibit-
ing polyploidy and disrupted microtubules (14).
As expected for a mitotic regulator, survivin is generally 
expressed in a cell cycle–dependent manner, peaking at G2–M 
and rapidly degraded in G1 (15). Survivin localizes to the cen-
tromeres during prometaphase/metaphase, translocates to the 
spindle midzone during anaphase/telophase, and eventually 
localizes to the midbody during cytokinesis (16–18). Con-
sistent with its dynamic localization, numerous studies have 
shown that survivin is a component of the chromosomal pas-
senger complex (CPC) that functions in the maintenance of an 
active spindle assembly checkpoint and in cytokinesis. In addi-
tion to survivin, the CPC is comprised of inner centromere 
protein (INCENP) (19), Aurora-B kinase (20), and Borealin/
Dasra B (21, 22). RNA interference (RNAi) knockdown of 
survivin or its partner proteins in U2OS and HeLa cells dis-
rupts proper targeting of the CPC to centromeres and the 
central spindle, suggesting that these proteins are mutually de-
pendent on each other for proper localization (21, 23–26). It 
has been proposed that survivin’s specifi  c role within the CPC 
is to target Aurora B kinase to diff  erent components of the 
mitotic apparatus, where it can phosphorylate its substrates.
A growing number of studies indicate survivin is expressed 
in normal adult cells, particularly human CD34+ hematopoi-
etic stem and progenitor cells (27–29), T lymphocytes (30, 31), 
polymorphonuclear neutrophils (32), and vascular endothe-
lial cells (33, 34), where it may regulate their proliferation or 
survival. Most recently, our laboratory has reported that survivin 
is diff  erentially required for the development of two closely 
related blood cells, erythroid cells and megakaryocytes (35). 
During terminal diff  erentiation, erythroid cells continue to 
  express survivin mRNA and protein throughout their matura-
tion, even after cell cycle exit, whereas megakaryocytes ex-
press an approximately fourfold lower level of survivin mRNA 
and no detectable protein (35, 36). Functionally, a reduction 
in survivin expression was found to interfere with erythroid 
cell formation, whereas its overexpression antagonized growth, 
maturation, and polyploidization of megakaryocytes (35). Fur-
thermore, survivin-defi  cient hematopoietic progenitors failed 
to give rise to either erythroid or megakaryocytic colonies in 
vitro (35). Based on these studies, survivin appears to have 
critical roles in normal hematopoietic cells, and the physiolog-
ical impact of survivin-targeted anticancer strategies on the 
hematopoietic compartment is unclear.
To elucidate precisely the role of survivin in in vivo he-
matopoiesis, we induced homozygous and heterozygous de-
letion of the survivin gene in the hematopoietic compartment 
in mice, using the Mx1-Cre transgene. We show that com-
plete loss of survivin in homozygous-fl  oxed Mx1-Cre animals 
resulted in rapid lethality. These mutant animals exhibited 
markedly hypocellular BM and spleen, a plethora of periph-
eral blood defects, and striking reductions in multiple hema-
topoietic progenitors, including hematopoietic stem cells. 
Surprisingly, acute heterozygous deletion of survivin led to 
defects in erythropoiesis in a subset of animals. Analysis of the 
erythroid lineage from spleens of these aff  ected mice dis-
played a dramatic reduction in enucleated erythrocytes, and 
the presence of immature erythroblasts that were megaloblas-
tic in nature. Collectively, we show that survivin is crucial for 
steady-state hematopoiesis in the adult, and that erythroid 
cells are sensitive to survivin levels.
RESULTS
Survivin is essential for adult hematopoiesis
Because survivin defi  ciency results in periimplantation letha-
lity (14), we used a conditional knockout strategy to study 
the requirement for survivin in in vivo hematopoiesis. Con-
ditional gene-targeted mice, with all four exons of the sur-
vivin gene fl  anked by loxP sites (31), were bred to mice 
expressing Cre recombinase under the control of the endog-
enous Mx1 locus, which can be transiently activated in re-
sponse to type-I IFN (37). Subsequently, mice harboring the 
Mx1-Cre transgene and either heterozygous or homozygous 
fl  oxed alleles of survivin were treated with polyinosinic-
  polycytidylic acid (pI-pC), which is a synthetic double-stranded 
RNA, to induce deletion of survivin in the hematopoietic 
compartment. pI-pC treatment of Mx1-Cre/sur fl / + and Mx1-
Cre/sur fl  /fl   adult mice resulted in robust excision of the sur-
vivin fl  oxed allele in BM cells as determined by PCR analysis 
(Fig. 1 A). To our surprise, administration of pI-pC to Mx1-
Cre/sur fl  /fl   mice caused rapid death (Fig. 1 B). Indeed, all of 
the animals became moribund within 10 d of pI-pC  treatment. 
In comparison, the control littermates showed no ill eff  ect 
after pI-pC injection, whereas the heterozygous-  deleted mice 
showed 20% mortality. Analysis of peripheral blood, BM, 
and spleen (a prominent site of   hematopoiesis in young mice) 
of survivin-defi   cient animals revealed a wide spectrum of 
  hematopoietic defects. As clearly evident in Fig. 1 D, there 
was almost a complete ablation of the BM of Mx1-Cre/sur fl  /fl   
mice. Consistent with this gross BM depletion, peripheral 
blood smears from survivin-deleted animals exhibited marked 
pancytopenia, including reticulocytopenia (Fig. 1 E). In 
  addition, a plethora of erythrocyte abnormalities, such as red 
cell fragmentation, anisopoikilocytosis, and hypochromia, 
were visible. Furthermore, Mx1-Cre/sur fl  /fl   mice had smaller 
and extremely hypo  cellular spleens (Fig. 1, C and F) caused 
by a reduced white and red pulp. The red pulp, which is a 
site of normal extramedullary hematopoiesis in young mice, 
was paucicellular. Most dramatic was the complete absence 
of nucleated erythroid progenitors that stained positive for 
the erythroid-specifi  c marker Ter119 in the spleens of Mx1-
Cre/sur fl / fl  mice, as shown by immunohistochemical analy-
sis for Ter119 (Fig. 1 G). Control mice that were treated 
with pI-pC did not display any of these phenotypes (Fig. 1, 
B–G). Interestingly, however, we observed an intermediate 
phenotype in survivin heterozygous-deleted mice (as dis-
cussed in Haploinsuffi   ciency of survivin leads to defects in 
erythropoiesis).
To better understand why the animals die within 2 wk of 
survivin depletion, we repeated the pI-pC injections on an-
other group of mice (8 wk of age) and analyzed their complete JEM VOL. 204, July 9, 2007  1605
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blood counts (CBCs) on days 7 and 11 after treatment. CBC 
analysis at day 7 revealed that survivin-depleted mice had 
lower hemoglobin and white cell and platelet counts compared 
with the control animals (unpublished data). By day 11, the 
survivin-depleted mice developed defi  nitive anemia. Thrombo-
cytopenia and leukopenia were refl  ected in the automated 
CBC, as well as on the peripheral blood smears shown in 
Fig. 1 E; homozygous-deleted animals displayed pancytopenia, 
with multiple defects in circulating erythrocytes. Therefore, 
we believe that the development of anemia in the periphery 
is mostly caused by underproduction, which may or may not 
be exacerbated by some peripheral destruction. Based on the 
presence of fragmented red cells in the periphery, we hypo-
thesize that a thrombotic microangiopathic process might 
contribute to the peripheral destruction of red cells in some of 
the mice. Furthermore, to investigate if the rapid morbidity 
and mortality of the survivin-depleted mice was caused by 
injury to nonhematopoietic tissues, gross and microscopic ex-
amination was performed on the major organs from control 
and survivin-depleted mice. There was no evidence of organ 
damage in the kidneys, lungs, livers, and hearts of the survivin-
depleted mice (unpublished data). Under the circumstances, 
we speculate that the morbidity and mortality observed in 
the survivin-depleted animals is secondary to BM failure. It is 
possible that anemia, infections caused by neutropenia, or 
hemorrhage caused by thrombocytopenia contribute to early 
morbidity and mortality in these animals.
Hematopoietic progenitors are susceptible to survivin loss
Because the BM histology indicated that survivin deletion af-
fected multiple hematopoietic lineages, we used fl  ow cytom-
etry to examine specifi  c cell populations in either the BM 
or spleen of control, Mx1-Cre/sur fl / +, and Mx1-Cre/sur fl / fl  
mice after pI-pC injection. In contrast to littermate controls, 
Gr-1+Mac-1+ myeloid cells and CD41+ megakaryocytes 
were both reduced in the BM of homozygous-deleted mice 
as early as 36 h after pI-pC induction (Fig. 2, A and B). C-kit+ 
progenitors were also dramatically diminished in the spleen 
of homozygous-deleted mice by 10 d of pI-pC administra-
tion (Fig. 2 C). Consistent with these results, total BM cells, 
isolated from homozygous-deleted mice 1 d after pI-pC in-
jection, failed to give rise to any myeloid, erythroid, or mega-
karyocytic colonies in colony-forming assays (unpublished data). 
The rapid time frame in which hematopoietic progenitors 
disappear after survivin excision suggests survivin is critical 
for the maintenance of hematopoietic cells.
We next focused on analyzing the eff  ect of survivin de-
letion in the erythroid lineage. During their maturation, 
erythroid cells progressively become smaller and exhibit chro-
matin condensation, hemoglobinization, cell cycle exit, and 
enucleation. As erythroblasts undergo terminal diff  erentiation, 
they also down-regulate expression of the transferrin receptor 
CD71 and up-regulate the erythroid-specifi  c marker Ter119. 
Erythroid cells can be segregated into four subsets by their 
CD71 and Ter119 expression level (R1 proerythroblasts, 
Ter119lowCD71high; R2 basophilic erythroblasts, Ter119high
CD71high; R3 polychromatophilic erythroblasts, Ter119high
CD71med; and R4 orthochromatophilic erythroblasts and reti-
culocytes, Ter119highCD71low) (38). To examine the conse-
quences of survivin deletion specifi  cally on erythropoiesis, we 
analyzed the distribution of erythroid subsets in the spleen of 
1-mo-old Mx1-Cre/sur fl /fl   mice 10 d after pI-pC administration. 
Compared with their littermate controls, homozygous-
deleted mice exhibited a marked reduction in the percentages 
of R1 and R2 subsets and an increase in the percentage of the 
R4 subset (Fig. 2 D). To investigate the erythroid perturba-
tion more carefully, we isolated R2 and R4 erythroid cells 
from pI-pC–treated control and Mx1-Cre/sur fl / fl  spleens by 
FACS for morphological evaluation. Because survivin deletion 
results in rapid BM ablation and early death in Mx1-Cre/sur fl / fl  
Figure 1.  Survivin is essential for adult hematopoiesis. (A) Deletion 
of the fl  oxed region was monitored by multiplex PCR using three primers 
to amplify the floxed, excised, and wild-type alleles. PCR of total BM 
cells from two representative examples 10 d after pI-pC administration. 
ex, excised; fl  , fl  oxed; wt, wild-type. (B) Survival curve for control (Surfl  /+; 
n = 19), heterozygous (MxCre Surfl  /+; n = 10), and homozygous (MxCre 
Surfl  /fl  ; n = 8) pups after pI-pC treatment. (C) Spleen weight with respect 
to body weight ± the SEM was recorded for control, heterozygous, and 
homozygous-deleted mice. (D) HE stained sections of sternum BM from 
control, heterozygous, and homozygous-deleted mice. (E) Peripheral blood 
smears from control, heterozygous, and homozygous-deleted mice were 
stained with May-Grünwald Giemsa. Red arrows, hypochromic erythro-
cytes. (F) HE spleen sections from mice in D. WP, white pulp; RP, red pulp. 
(G) Anti-Ter119 immunohistochemical analysis of spleen sections from 
mice in D. Black arrows, nucleated Ter119+ erythroid cells; arrowheads, 
enucleated Ter119+ erythrocytes.1606  SURVIVIN IS ESSENTIAL FOR HEMATOPOIESIS | Leung et al.
mice, the experiment was performed at an earlier time point, 
4 d after pI-pC injection. Survivin excision in total spleen cells 
was confi  rmed by PCR analysis (Fig. 3 A). At this early time 
point, the spleens from survivin homozygous-deleted mice 
were comparable in size to those of control littermates and 
harbored similar absolute numbers of R4 cells, but strikingly 
fewer R2 cells (Fig. 3 B). Morphological evaluation of the R4 
population by both May-Grünwald Giemsa and   benzidine 
staining revealed that the majority of cells in survivin-deleted 
animals were mature, hemoglobinized, and enucleated eryth-
rocytes that were indistinguishable from those of controls 
(Fig. 3 C). These data support an essential role for survivin in 
proliferating proerythroblasts and basophilic erythroblasts. In 
contrast, R4 cells, which had already exited the cell cycle and 
extruded their nuclei, were not aff  ected by survivin loss, and 
the total number of cells within the R4 population was not 
signifi  cantly altered, resulting in an apparent relative increase 
in the percentage of cells in the R4 gate.
Survivin-depleted erythroblasts exhibit altered cell cycle, 
increased cell death, and polyploidy
To determine whether aberrant proliferation or increased 
cell death was responsible for the erythroid defect, we next 
analyzed the cell cycle profi  le and DNA content of survivin-
depleted erythroid precursors. BM cells from control and 
Mx1-Cre/sur fl / fl  mice were harvested 48 h after pI-pC treat-
ment and stained with DAPI and antibodies against CD71 and 
Ter119. Analysis of survivin-defi  cient erythroblasts showed 
increased G1 and decreased S phase cells, indicating that these 
cells were either cell cycle-arrested or had exited the cell cycle 
faster (Fig. 4 A). In addition, survivin-defi  cient erythroblasts 
exhibited an increase in cells with ≥4 N DNA content, as 
well as a moderate increase in cells with sub-G1 DNA (Fig. 4 B). 
The increase in the number of cells with sub-G1 DNA sug-
gests that some of the cells have undergone cell death, either as 
a consequence of aberrant cell cycle progression or initiation 
of apoptosis.
We next investigated whether the death seen in these 
cells was a consequence of activation of the intrinsic mito-
chondrial apoptotic pathway. If survivin depletion resulted in 
initiation of this pathway, then ectopic Bcl-2 expression in 
these cells might rescue the phenotype caused by survivin 
loss. To address this question, we used vav-Bcl-2 transgenic 
mice, in which constitutive expression of the human Bcl-2 
cDNA is restricted to nucleated hematopoietic cells by the 
vav promoter (39). To assess the ability of vav-Bcl-2 to pro-
mote the survival of erythroid progenitors, lineage-negative 
BM cells from vav-Bcl-2 transgenic mice or their wild-type 
littermates were subjected to varying doses of gamma irradia-
tion (0, 200, or 300 rads) and plated in erythroid colony-
forming assays with IL3, SCF, and EPO. As demonstrated in 
Fig. 4 C, vav-Bcl-2, indeed, promoted the survival of ery-
throid progenitors in response to gamma irradiation. In fact, 
after treatment with 200 or 300 rads of gamma irradiation, 
Figure 2.  Survivin deletion leads to a reduction in hematopoietic 
progenitors. (A) Gr1+Mac1+ BM cells harvested from mice 36 h after 
treatment with one dose of pI-pC (n = 2). (B) CD41+ BM cells from mice, 
as described in A. (C) Flow cytometric analysis of c-kit+–stained spleen 
cells from 1-mo-old Surfl  /+, MxCre Surfl  /+, and MxCre Surfl  /fl   pups 10 d 
after 2 doses of pI-pC. Percentages are shown. (D) CD71+Ter119+ spleen 
cells from mice, as described in C. Results shown are representative of 
four independent experiments.
Figure 3.  Survivin deletion diminishes proliferating CD71+Ter119+ 
erythroid cells. (A) Survivin deletion in total splenic cells from control 
(Sur fl  /fl  ) and homozygous-deleted (MxCre Sur fl  /fl  ) mice 4 d after pI-pC 
treatment was confi  rmed by PCR. (B) FACS profi  les for sorted CD71/Ter119 
R2 and R4 erythroid populations are shown with both percentages and 
absolute cell numbers. (C) Cytospin slides of FACS-sorted R2 and R4 ery-
throid cells were stained with either May-Grünwald Giemsa or benzidine. JEM VOL. 204, July 9, 2007  1607
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the vav-Bcl-2 transgene led to a twofold increase in erythroid 
colony formation in vitro, compared with wild-type controls. 
Furthermore, vav-Bcl-2 also prolonged the survival of ery-
throid progenitors after 3 d of EPO deprivation (unpublished 
data). To determine whether overexpression of Bcl-2 can 
rescue the defects caused by survivin defi  ciency, we crossed 
vav-Bcl-2 transgenic mice to Mx1-Cre/sur fl  /fl   mice to generate 
Mx1-Cre/sur fl  /fl  ; Bcl-2 animals. Bcl-2 and survivin expression 
were detected by Western blot analysis of protein extracts 
prepared from the spleens of pI-pC–treated control, Bcl-2 
transgenic, or Mx1-Cre/sur fl / fl ; Bcl-2 mice (Fig. 4 D). Although 
ectopic expression of Bcl-2 under the vav promoter protected 
erythroid cells on a wild-type survivin background, it failed 
to rescue the smaller spleen, loss of erythroid progenitors, and 
eventual demise of Mx1-Cre/sur fl  /fl  ; Bcl-2 mice after survivin 
deletion (Fig. 4 E).
Haploinsuffi  ciency of survivin leads to defects 
in erythropoiesis
We previously reported that heterozygous loss of survivin 
caused a nearly 50% reduction in erythroid colony formation, 
but a much less dramatic change in the number of mega-
karyocytic colonies (35). These fi  ndings suggested that the 
erythroid lineage might be uniquely sensitive to the dosage of 
survivin. In this current study, we observed defects in a pro-
portion of the heterozygous-deleted mice that are consistent 
with a dose-dependence for survivin in erythroid cells. First, 
2 out of the 10 Mx1-Cre/sur fl l + animals, but none of the con-
trol animals, died within 10 d of pI-pC treatment (Fig. 1 B). 
Second, four out of the fi  ve BM sections from heterozygous-
deleted mice were identifi  ed as harboring fewer erythroid 
precursors in a blinded analysis by a pathologist (S. Gurbuxani; 
Fig. 1 D and not depicted). Additionally, peripheral blood 
smears from these mice displayed an increase in hypochromic 
erythrocytes (Fig. 1 E, red arrows), which were not observed 
in any pI-pC–treated control animals.
Furthermore, analysis of the CD71/Ter119 erythroid 
population by flow cytometry revealed that 20% of the 
heterozygous-deleted animals harbored an altered proportion of 
erythroid cells, with aff  ected animals displaying an increased 
proportion of R2 cells and a concomitant decrease in the R4 
population (Fig. 2 D and Fig. 5 A). In the data depicted in 
Fig. 5 A, which are representative of the aff  ected group of 
animals, nearly half as many R4 cells and a greater number of 
R2 cells were isolated from the heterozygous-deleted spleen 
in comparison to the control spleen. To further explore the 
nature of this defect, R2 and R4 cells from pI-pC–treated 
control, and Mx1-Cre/sur fl l + mice were collected by FACS. 
Excision of the fl  oxed allele was confi  rmed by PCR analy-
sis (Fig. 5 B). May-Grünwald Giemsa staining of purifi  ed 
cells revealed that although the R2 progenitors appeared sim-
ilar, the R4 erythroid population was distinctly diff  erent in 
the two groups (Fig. 5, C and D). Heterozygous survivin-
defi  cient R4 cells exhibited a striking increase in the proportion 
of nucleated erythroblasts, with a concomitant decrease in 
enucleated erythrocytes. Interestingly, the R4 population of 
survivin heterozygous-deleted erythroblasts appeared imma-
ture and possessed less condensed, larger nuclei, which is in-
dicative of a block in terminal diff  erentiation. Although this 
phenotype was not fully penetrant, the megaloblastic features 
observed in a signifi  cant proportion of heterozygous-deleted 
animals suggest that survivin plays a novel role in erythroid 
terminal diff  erentiation.
Defects caused by survivin deletion are cell autonomous
Whereas the preceding data suggest that survivin defi  ciency 
results in impaired proliferation and subsequent loss of hema-
topoietic progenitors, Mx1-Cre excision is not absolutely 
limited to hematopoietic cells (37). Therefore, to determine 
whether the requirement for survivin is cell autonomous, we 
transplanted total CD45.2+-nucleated BM cells from control, 
Mx1-Cre/sur fl / +, or Mx1-Cre/sur fl / fl  mice, along with wild-
type CD45.1+/CD45.2+ support cells, into lethally irradiated 
Figure 4.  Survivin homozygous-deleted erythroid cells exhibit 
altered cell cycle, increased cell death, and polyploidy. (A) Control 
(Surfl  /+), heterozygous (MxCre Surfl  /+), and homozygous (MxCre Surfl  /fl  ) 
mice were treated with one dose of pI-pC. BM cells were isolated 48 h 
later and stained for CD71, Ter119, and DAPI for fl  ow cytometric cell cycle 
analysis. Cell cycle phases on gated proliferating CD71+Ter119+ cells were 
calculated using Watson Pragmatic model. The data are representative of 
three sample sets from two independent experiments. (B) SubG1 DNA and 
ploidy analysis for A. (C) Erythroid colony-forming assays of untreated or 
gamma-irradiated (200 or 300 rads; n = 3) lineage-negative BM cells 
from vav-Bcl-2 transgenic mice or their wild-type littermates. Mean 
numbers of pure and mixed erythroid colonies ± the SEM are shown. 
(D) Western blot, probed for survivin and Bcl-2, of spleen extracts prepared 
from Surfl  /+, Surfl  /fl  ; Bcl-2, and MxCre Surfl  /fl  ; Bcl-2 pups 10 d after 2 doses 
of pI-pC treatment. Heat shock protein 70 (Hsc70) was included as a loading 
control. (E) Flow cytometric analysis of CD71/Ter119 stained spleen cells 
from mice, as described in C. Results are representative of fi  ve out of 
seven MxCre Surfl  /fl  ; Bcl-2 pups from four independent experiments.1608  SURVIVIN IS ESSENTIAL FOR HEMATOPOIESIS | Leung et al.
CD45.1+ congenic recipients (Fig. 6 A). Engraftment of do-
nor cells was fi  rst verifi  ed by staining for CD45 surface marker 
expression in peripheral blood 5 wk after transplantation. 
The engraftment of CD45.2+ cells ranged from 7 to 69% 
(Fig. 6 B). Recipients were then treated with pI-pC, and the 
contribution of CD45.2+ cells to the hematopoietic com-
partment was assessed. Survivin excision led to pronounced 
depletion of CD45.2+ cells in the peripheral blood, support-
ing a role for survivin in hematopoietic stem and progenitor 
cells (Fig. 6 C). Administration of pI-pC to Mx1-Cre/sur fl  /fl   
transplanted mice also led to near complete disappearance of 
the BM CD45.2+ hematopoietic cells within 2 wk of pI-pC 
treatment in all fi  ve mice analyzed (Fig. 6, D and E). No sig-
nifi  cant changes were observed in either control or Mx1-
Cre/sur fl l + transplanted mice. These data show that there is a 
cell autonomous requirement for survivin in hematopoietic 
progenitors. Next, to determine whether HSCs are also sus-
ceptible to survivin deletion, we elucidated the origin of the 
HSC populations in control and Mx1-Cre/sur fl  /fl   transplanted 
animals 10 wk after pI-pC administration. Flow cytometric 
analyses revealed that the lin–c-kit+Sca-1+ HSC populations 
in Mx1-Cre/sur fl  /fl   transplanted mice were exclusively derived 
from wild-type CD45.1+/CD45.2+ support cells, whereas the 
HSC populations in control animals expressed either CD45.2+ 
alone or CD45.1+/CD45.2+ cell surface markers (Fig. 7).
D  I  S  C  U  S  S  I  O  N 
We show that survivin is an essential gene in the adult and is 
indispensable for the proliferation and maintenance of both 
hematopoietic stem and progenitor cells. Similar to inducible 
deletion of the antiapoptotic Bcl-2 family member myeloid 
leukemia-1 (MCL-1) in mice, homozygous deletion of sur-
vivin resulted in rapid death, ablation of the BM, and loss of 
early BM progenitor populations, including HSCs (40). Con-
sistent with our fi  ndings, T lineage-specifi  c survivin knock-
out mice revealed critical requirements for survivin in the 
Figure 5.  Survivin haploinsuffi  ciency in erythroid maturation. 
(A) FACS sort profi  le of CD71/Ter119-stained R2 and R4 erythroid populations 
from spleens of control (MxCre) and heterozygous-deleted (MxCre Surfl  /+) 
mice 10 d after pI-pC administration. Percentages and absolute cell 
numbers are shown. (B) Survivin deletion in total splenic cells from MxCre 
and MxCre Surfl  /+ mice was confi  rmed by PCR. (C) Cytospin slides of 
FACS-sorted R2 erythroid cells stained with May-Grünwald Giemsa. 
(D) May-Grünwald   Giemsa–stained cytospin slides of FACS-sorted R4 
erythroid cells. Arrows, nucleated erythroblasts. (bottom) The table sum-
marizes percentages of erythroblasts and erythrocytes for the sorted R4 
population from each mouse.
Figure 6.  Cell-autonomous defects of survivin deletion. (A) Mice 
with chimeric BM were generated by transplanting conditionally gene 
targeted CD45.2+ BM cells with wild-type CD45.1+/CD45.2+ BM support 
cells into lethally irradiated congenic CD45.1+ recipients. A subset of mice 
was treated with pI-pC after BM transplantation. (B) Table depicts per-
centage of donor CD45.2+ cells that has engrafted for each mouse before 
pI-pC administration, as determined by CD45.1/CD45.2 staining of periph-
eral blood. (C) Mean percentages of CD45.2+ cells ± the SEM in the 
  peripheral blood of Surfl  /+ (n = 3; gray line) and MxCre Surfl  /fl   (n = 9; black 
line) mice after pI-pC treatment. Initial engraftment of CD45.2+ was nor-
malized to 100% for each mouse. (D) Flow cytometric analysis of CD45.1/
CD45.2 stained BM cells from representative Surfl  /+ and MxCre Surfl  /fl   mice 
in the absence or presence of pI-pC treatment. Percentages of CD45.2+ 
cells (P1) and CD45.1+/CD45.2+ cells (P2) were determined for gated large 
nucleated cells. (E) Histogram depicts mean contribution of BM CD45.2+ 
cells ± the SEM of Surfl  /+ (n = 2, untreated; n = 3, plus pI-pC), MxCre 
Surfl  /+ (n = 2, untreated; n = 3, plus pI-pC), and MxCre Surfl  /fl   (n = 2, 
untreated; n = 5, plus pI-pC) transplanted mice.JEM VOL. 204, July 9, 2007  1609
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development and homeostasis of T cells (30, 31). In response 
to mitogen-induced proliferation, survivin-defi  cient T cells 
exhibited p53-mediated cell cycle arrest, a spindle formation 
defect, and spontaneous cell death. In addition, p53 inactiva-
tion or introduction of Bcl-2 failed to rescue the thymocyte 
developmental defects caused by survivin defi  ciency (30). In 
light of these published works, our study suggests survivin 
may function as both a chromosomal passenger protein and 
an inhibitor of apoptosis in the maintenance of hematopoi-
etic stem and progenitor populations.
In addition, we demonstrate that haploinsuffi   ciency of sur-
vivin aff  ects erythroid terminal maturation. Erythroid progen-
itors undergo a series of three to four rapid “diff  erentiation 
divisions” to give rise to mature, enucleated, and hemoglo-
binized erythrocytes (41). During this process, the G1 phase of 
the cell cycle is reduced from 11 h to 5 h, and the cell size is 
reduced from a 12-μm proerythroblast to a 4-μm erythrocyte 
(mouse). This altered cell cycle progression is accompanied 
by extensive changes in gene expression, including a rapid 
down-regulation of D-type cyclins and their partner, cyclin-
dependent kinase type 4 (cdk4). In contrast, expression levels of 
S- and G2–M-associated cell cycle regulators, such as cyclin A 
and cdk1/cdc2, are transiently up-regulated. In this study, we 
show a dose-dependent requirement for survivin in erythro-
poiesis. We previously reported that survivin levels increase as 
erythroid cells mature, with both mRNA and protein present 
in cells throughout even the late orthochromatic stage. In fact, 
erythroid cells express approximately fourfold higher levels of 
survivin mRNA and protein than the related megakaryocytic 
lineage during their terminal diff  erentiation (35). Therefore, 
reduced levels of key mitotic regulators, including survivin, 
may compromise the effi   ciency of the cell cycle machinery 
and subsequently, lead to defects in erythroid maturation. 
Consistent with this model, mice heterozygous for BubR1, 
which is a spindle assembly checkpoint protein, exhibited de-
creased erythropoiesis and a higher frequency of anemia (42). 
Interestingly, stable association of BubR1 to kinetochores and 
maintenance of the spindle assembly checkpoint is critically 
dependent on survivin (12, 24). In the presence of reduced 
survivin levels, Aurora B kinase, INCENP, and Borealin 
may less effi   ciently localize to diff  erent components of the 
mitotic apparatus, including the inner centromeres, where the 
CPC plays an important auxiliary role in spindle checkpoint 
surveillance. Because Aurora B, INCENP, and survivin form 
a   complex that is required for multiple aspects of mitosis and 
cytokinesis, a reduction in survivin levels likely disrupts proper 
targeting of Aurora B kinase to its substrates. It remains to be 
determined whether survivin has a novel role in erythroid ter-
minal diff  erentiation independent of its mitotic function.
Several preclinical studies have shown that disrupting 
survivin expression or function in cancer cells decreases their 
proliferation and enhances apoptosis (43). The absence of 
signifi  cant side eff  ects on hematopoietic cells reported in 
these studies may be caused by local intratumor injection and 
minimal systemic dissemination of anti-survivin therapies. 
More recently, shepherdin, which is a small peptide that 
destabilizes survivin by blocking its interaction with the 
molecular chaperone heat shock protein 90 (Hsp90), has been 
shown to aff  ect human CD34+ hematopoietic progenitor 
colony formation in vitro (44). In that study, treatment of 
CD34+ cells with shepherdin inhibited precursor erythroid 
burst-forming unit colony formation and, at slightly higher pep-
tide concentrations, granulocyte–macrophage colony-forming 
units and granulocyte erythrocyte macrophage megakaryocyte 
colony-forming units. Our study confi  rms that the hemato-
poietic system is extremely sensitive to survivin disruption and 
emphasizes the need for innovative and selective anti-survivin 
cancer therapies.
MATERIALS AND METHODS
Generation of Mx1-Cre/Sur fl /fl   and Mx1-Cre/Sur fl /fl  ; Bcl-2 mice. Con-
ditionally gene-targeted mice, with all four exons of the survivin gene fl  anked 
by loxP sites, were obtained from A. Winoto (University of California, 
Berkeley, Berkeley, CA) (31). Mx1-Cre transgenic mice harboring Cre recom-
binase under the control of the interferon-responsive Mx1 promoter in a 
C57BL/6 background were purchased from The Jackson Laboratory. Vav-
Bcl-2 transgenic mice, in which constitutive expression of a human Bcl-2 
cDNA is driven by the promoter of the vav gene, were provided by J. Adams 
(Walter and Eliza Hall Insitute of Medical Research, Victoria, Australia) and 
K. Macleod (University  of Chicago, Chicago, IL) (39). To generate Mx1-
Cre/sur fl / + mice, sur fl  /fl   mice were crossed to Mx1-Cre transgenic mice. Mx1-
Cre/sur fl / + mice were subsequently bred to sur fl  /fl   mice to produce littermates 
with the following genotypes: sur fl / +, sur fl  /fl  , Mx1-Cre/sur fl / +, and Mx1-Cre/
sur fl  /fl  . To generate Mx1-Cre/sur fl  /fl  ; Bcl-2 mice, Mx1-Cre/sur fl  /fl   mice were 
crossed to Bcl-2 transgenic mice to obtain Mx1-Cre/sur fl / +; Bcl-2 mice, 
which were then bred to sur fl / + mice. All animal research was approved by 
the University of Chicago and Northwestern University Institutional Ani-
mal Care and Use Committees.
Figure 7.  Hematopoietic stem cells are susceptible to survivin 
deletion. The c-kit and Sca-1 profi  les of lineage-negative BM cells 
(negative for CD5, B220, CD11b, Ter119, Gr-1, 7–4) from Surfl  /+ (n = 1) 
and MxCre Surfl  /fl   (n = 2) transplanted mice 10 wk after 3 doses of pI-pC 
(left plots). Lin–c-kit+Sca-1+ cells were gated and analyzed for CD45.1 
and CD45.2 cell surface markers (right plots). Numbers indicate percentages 
of cell populations.1610  SURVIVIN IS ESSENTIAL FOR HEMATOPOIESIS | Leung et al.
Mouse genotyping. Mouse genotyping was performed by PCR of tail 
DNA. For genotyping the Mx1-Cre transgene, the Mx1-Cre forward (5′-
gcctgcattaccggtcgatgcaacga-3′) and Mx1-Cre reverse (5′-gtggcagatggcgcg-
gcaacaccatt-3′) primers were used to amplify a 725-bp PCR product. Three 
primers (Adv17, Adv25, and Adv28) were used to genotype the wild-
type, fl  oxed, and Cre-deleted survivin allele, as previously described (31). For 
genotyping the vav-Bcl-2 transgene, primers against the SV40 poly(A) DNA 
sequence were used (39).
Histological analysis. Newborn (10–14 d) mice received two intraperito-
neal injections (13 μg/g body weight) of pI-pC (GE Healthcare) every other 
day to induce survivin deletion. Sternum BM and spleen were isolated 10 d 
later, fi  xed overnight in formalin (Sigma-Aldrich), and processed for histo-
logical analysis. Serial sections were stained with hematoxylin and eosin 
(HE), and peripheral blood smears were stained with May-Grünwald   Giemsa 
using standard protocols. Immunohistochemistry was performed on deparaf-
fi  nized spleen sections with anti-Ter119 antibody (BD Biosciences).
Flow cytometric analysis and cell sorting. To obtain BM cells, mouse 
femurs and tibiae were fl  ushed with PBS, and cells were separated by pas-
sage through a 20-gauge syringe. For spleen cells, spleens were cut into 
small pieces and subsequently disaggregated with an 18-gauge syringe. 
Cells were resuspended in PBS containing 1 mM EDTA and 1% bovine 
serum albumin (Sigma-Aldrich) to reduce aggregates and nonspecifi  c stain-
ing, respectively. The cells were stained with diff  erent combinations of 
c-kit, Gr-1, Mac-1, CD41, CD71, and Ter119 antibodies, conjugated to 
APC, PE, or FITC (BD Biosciences). Finally, surface marker expression 
was analyzed using a FACSCanto fl  ow cytometer (BD Biosciences) and 
FlowJo software. To isolate discrete erythroid populations, spleen cells 
were fi  rst stained with FITC-conjugated CD71 and PE-conjugated Ter119 
antibodies. Then, based on the CD71 and Ter119 expression level, ery-
throid subpopulations were purifi  ed using a MoFlo-HTS cell sorter (Dako-
Cytomation). FACS-sorted cells were cytospun onto slides and stained 
with either May-Grünwald Giemsa or benzidine Wright Giemsa for mor-
phological evaluation.
Cell cycle analysis. Adult (6–8 wk) mice were injected intraperitoneally 
with one dose of pI-pC. BM cells were isolated 48 h later and stained with 
FITC anti-CD71 and PE anti-Ter119 antibodies. Cells were fi  xed with 2% 
paraformaldehyde (Sigma-Aldrich) and 70% ethanol to preserve cell surface 
antibody-conjugated fl  uorochrome staining. Subsequently, cells were treated 
with 2 N HCl/0.5% Triton X-100, followed by 0.1 M sodium tetraborate, 
and DNA was stained with DAPI (Sigma-Aldrich) at 4°C overnight. The 
cell cycle profi  le of CD71+ Ter119+ erythroid cells was analyzed using a 
LSR-II fl  ow cytometer (BD Biosciences) and FlowJo software.
Erythroid colony-forming assays. Primary mouse BM cells were col-
lected from vav-Bcl-2 transgenic mice and their wild-type littermates and 
enriched for progenitors with the EasySep negative-selection mouse hema-
topoietic progenitor-enrichment kit (StemCell Technologies). The cells were 
either left untreated or irradiated with 200 or 300 rads in a Cesium-137 
irradiator. To evaluate erythroid colony formation, 25,000 cells were plated 
in MethoCult 3234 (StemCell Technologies), supplemented with IL3, SCF, 
and 10 U/ml EPO. Pure burst-forming unit erythroid and mixed colonies 
were enumerated after 10 d.
BM transplantation. C57BL/6 CD45.1+ congenic recipients (6–8 wk) 
were purchased from The Jackson Laboratory and placed on Bactrim-
  containing water 1 wk before lethal irradiation. Mice were irradiated with a 
total of 1,200 rads in split doses (800 rads, and then 400 rads 4 h later). Total 
nucleated BM cells (106), marked by the CD45.2+ allele from untreated 
control, Mx1-Cre/sur fl / +, or Mx1-Cre/sur fl / fl  mice, along with CD45.1+/
CD45.2+ support cells (0.5 × 106), were injected retroorbitally into lethally 
irradiated CD45.1+ recipients that were anesthetized with Nembutal (Abbott 
Laboratories). CD45.2+ and CD45.1+/CD45.2+ BM cells were allowed to 
engraft for 5 wk after transplantation. After the engrafting, peripheral blood 
from recipient mice was obtained by tail vein bleeding, subjected to red 
blood cell lysis, and stained with PE-Cy5.5–conjugated CD45.1 (eBiosci-
ence) and FITC-conjugated CD45.2 (BD Biosciences) antibodies to verify 
donor cell engraftment by fl  ow cytometric analysis. A subset of the recipients 
was injected with 2 doses of pI-pC, whereas the remainder served as 
  untreated controls. BM cells from pI-pC–treated and control animals were 
isolated 2 wk after pI-pC administration and analyzed for the presence of 
CD45.2+ and CD45.1+/CD45.2+ donor cells. For HSC analysis, BM cells 
from transplanted mice, 10 wk after 3 doses of pI-pC, were depleted of 
mature hematopoietic lineages, expressing surface antigens CD5, CD11b, 
B220, Gr-1, Ter119, and 7–4, with EasySep (StemCell Technologies). 
Lineage-negative cells were stained for APC anti–c-kit, PE-Cy7 anti–Sca-1 
(eBioscience), FITC anti-CD45.2, and PE-Cy5.5 anti-CD45.1 antibodies 
and analyzed by FACSCanto fl  ow cytometer.
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